L’Oréal is investing in dermatological beauty treatments and injectables: the company is doubling its stake in Swiss skincare company Galderma to 20%. The French cosmetics group is thus (partly) backtracking.
Co-founded by L’Oréal
The market for aesthetic injections is growing rapidly, making this segment a strategic priority for L’Oréal as well. Following recent investments in clinics in China and the United States, the cosmetics group is acquiring a further 10% of the shares in Galderma. “Our initial strategic investment in Galderma in 2024 has proven to be very successful,” said L’Oréal CEO Nicolas Hieronimus.
